Wendy Corbin
Family · Chipley, FLNPI 1598898835
Payments from drug & device makers
Across 94 payments — averaging $15.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$318
- Novo Nordisk$305
- AbbVie$185
- AstraZeneca$145
- Amarin Pharma, Inc.$133
- GSK$64
- plus $314 from 14 others
What the payments were for
- Food & beverage$1,464100%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 21 | $318 |
| Novo Nordisk | 16 | $305 |
| AbbVie | 17 | $185 |
| AstraZeneca | 8 | $145 |
| Amarin Pharma, Inc. | 7 | $133 |
| GSK | 4 | $64 |
| Novartis | 3 | $56 |
| Exact Sciences | 2 | $38 |
| Astellas Pharma US Inc | 2 | $29 |
| Amgen | 2 | $29 |
| Grifols USA, LLC | 1 | $24 |
| Dexcom, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $20 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Pfizer | 1 | $15 |
| Merck | 1 | $15 |
| Biohaven Pharmaceuticals, Inc. | 1 | $14 |
| Phathom Pharmaceuticals, Inc. | 1 | $14 |
| Seqirus USA Inc | 1 | $12 |
| Genentech USA, Inc. | 3 | $8 |
How this compares
$1,465 in reported general payments places this provider in the 75th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 103 | $89,400 |
| TrulicityDulaglutide | 64 | $88,464 |
| EliquisApixaban | 63 | $72,864 |
| MounjaroTirzepatide | 45 | $66,658 |
| JardianceEmpagliflozin | 46 | $62,807 |
| OzempicSemaglutide | 33 | $48,742 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 43 | $44,421 |
| RybelsusSemaglutide | 23 | $35,395 |
| LinzessLinaclotide | 19 | $24,552 |
| VascepaIcosapent Ethyl | 42 | $18,987 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 16 | $17,146 |
| JanuviaSitagliptin Phosphate | 16 | $13,031 |
| Tresiba Flextouch U-100Insulin Degludec | 18 | $11,993 |
| MyrbetriqMirabegron | 13 | $6,935 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $6,450 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $318 | $155,121109 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $145 | $116,420148 claims |
| Novo NordiskOzempic, Rybelsus | $305 | $84,13756 claims |
| PfizerEliquis | $15 | $72,86463 claims |
| GSKTrelegy Ellipta | $64 | $44,42143 claims |
| AbbVieLinzess, Synthroid | $185 | $27,38953 claims |
| MerckJanuvia | $15 | $13,03116 claims |
| Astellas Pharma US IncMyrbetriq | $29 | $6,93513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 14,618 family providers in Florida.
Other family in Chipley
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.